FeesSafety
Pluang+

FTI Consulting posts record Q3 revenue of $1.013B with 6% growth, raises adjusted EPS guidance for 2026.

Company Fundamentals
29 Oct 2026, 14:30 WIB
GlobeNewsWire
View Source
Bullish
FTI Consulting posts record Q3 revenue of $1.013B with 6% growth, raises adjusted EPS guidance for 2026.

FTI Consulting reported record third-quarter 2026 revenues of $1.013 billion, up 6% from the prior year, driven by growth across all five business segments. Despite a net income decline due to a $46 million special charge and higher expenses, adjusted EPS rose 48% to $3.84. The company reaffirmed its full-year revenue guidance and raised its adjusted EPS forecast to between $9.50 and $10.00. Cost-saving measures are expected to yield $80 million in annual savings, with a special charge anticipated in Q4 2026.

FTI Consulting's record third-quarter 2026 revenues provide context for readers interested in financial sector trends. For readers following financial stocks, here is Pluang's market snapshot as of Oct 29, 2026 17:53 WIB: out of 142 priced Financials-sector US stocks tradable on Pluang, 94 rose and 43 fell today. Notable movers include RIOT at USD 14.01 with a 1-day change of -3.04% and a typical hold time of 18 days, TROW at USD 107.01 with a 1-day change of +2.89% and a typical hold time of 117 days, and BMNR at USD 21.44 with a 1-day change of -2.77% and a typical hold time of 4 days.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
1 hour ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
1 hour ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
2 hours ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
2 hours ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App